12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Truvada emtricitabine/tenofovir regulatory update

FDA accepted and granted Priority Review to an sNDA from Gilead for once-daily Truvada emtricitabine/tenofovir for pre-exposure prophylaxis (PrEP) to reduce risk...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >